Pages that link to "Q49029662"
Jump to navigation
Jump to search
The following pages link to ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma (Q49029662):
Displaying 50 items.
- ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma (Q21129306) (← links)
- ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature (Q21198873) (← links)
- Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma (Q21285042) (← links)
- Anaplastic lymphoma kinase: signalling in development and disease (Q24312329) (← links)
- Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting in nasal cavity: a case report and review of literature (Q26862702) (← links)
- Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas (Q27851640) (← links)
- Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib (Q28083711) (← links)
- Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast Cancers (Q28728499) (← links)
- ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions (Q33707493) (← links)
- Targetome profiling and functional genetics implicate miR-618 in lymphomagenesis (Q33779176) (← links)
- ALK-positive diffuse large B-cell lymphoma of the duodenum: A case report and review of the literature (Q33837483) (← links)
- Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature (Q33859852) (← links)
- Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide. (Q34399099) (← links)
- ALK-driven tumors and targeted therapy: focus on crizotinib (Q34414378) (← links)
- ALK-immunoreactive neoplasms. (Q36092957) (← links)
- What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? (Q36132014) (← links)
- Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. (Q36158713) (← links)
- Diffuse large B-cell lymphomas with plasmablastic differentiation (Q36223630) (← links)
- Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. (Q36446169) (← links)
- Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities (Q36622610) (← links)
- ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature (Q36727991) (← links)
- Nodal aggressive B-cell lymphomas: a diagnostic approach (Q36763463) (← links)
- Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity (Q37268913) (← links)
- Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy (Q37411178) (← links)
- ALK: a tyrosine kinase target for cancer therapy (Q37518624) (← links)
- Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy (Q37799137) (← links)
- Pediatric Anaplastic Lymphoma Kinase–Positive Large B-cell Lymphoma: A Case Report and Review of the Literature (Q37990975) (← links)
- Promising Personalized Therapeutic Options for Diffuse Large B-cell Lymphoma Subtypes with Oncogene Addictions (Q38022591) (← links)
- Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma (Q38042570) (← links)
- Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology (Q38141512) (← links)
- ALK-positive cancer: still a growing entity. (Q38184584) (← links)
- Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target (Q38326252) (← links)
- Detecting and targetting oncogenic fusion proteins in the genomic era. (Q38336067) (← links)
- Novel ALK inhibitors in clinical use and development. (Q38427240) (← links)
- Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas (Q38433704) (← links)
- Multi-lineage interrogation of the performance characteristics of a split-signal fluorescence in situ hybridization probe for anaplastic lymphoma kinase gene rearrangements: a study of 101 cases characterized by immunohistomorphology on fixed archiv (Q38442806) (← links)
- CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases (Q38605346) (← links)
- ROS1 fusions in cancer: a review (Q38852070) (← links)
- Anaplastic lymphoma kinase positive large B-cell lymphoma: Literature review and report of an endoscopic fine needle aspiration case with tigroid backgrounds mimicking seminoma. (Q38968118) (← links)
- Targeting ALK: Precision Medicine Takes on Drug Resistance (Q39103431) (← links)
- Diagnosis and treatment of CD20 negative B cell lymphomas (Q39132786) (← links)
- Gene and miRNA expression changes in squamous cell carcinoma of larynx and hypopharynx (Q40492891) (← links)
- Relapsed anaplastic lymphoma kinase-positive large B-cell lymphoma expressed cluster of differentiation 4 and cytokeratin: An initially misdiagnosed case corrected by immunoglobulin κ locus gene rearrangement detection (Q40979129) (← links)
- Clathrin heavy chain gene fusions expressed in human cancers: analysis of cellular functions (Q41807334) (← links)
- Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas (Q42004966) (← links)
- NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases. (Q42254184) (← links)
- Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas (Q42586803) (← links)
- Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. (Q42639021) (← links)
- Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent (Q43104067) (← links)
- Diagnostic impact of molecular lineage analysis on paraffin-embedded tissue in hematolymphoid neoplasia reclassified by current WHO criteria (Q44305871) (← links)